These are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information. For more information, please see our FAQs.
Coban_et-al_FinalCombined-RXIV_submit3260546.pdf (2.71 MB)

Attacking COVID-19 Progression using Multi-Drug Therapy for Synergetic Target Engagement

revised on 07.07.2020, 16:02 and posted on 16.07.2020, 18:35 by Mathew Coban, Juliet Morrison, William Freeman, Evette S. Radisky, Karine Le Roch, Thomas Caulfield
We are presenting our on going studies with inhibitory research on Tmprss2, S-protein:Ace2, and 3CLpro using compound screening coupled with X-ray crystallography, molecular modeling, live virus screening using host human cells (BSL3 facility at UC Center for Infectious Disease and Vector Research, and organ-on-a-chip at Harvard Medical School for safety profiling before proceeding to animal models with InVivo BioSystems for ADMET.
We have derived a useful chemical toolkit of 350 compounds for the community to study with biochemical assays and other biophysical-chemical studies that will prove useful in searching for optimal inhibitors of these targets to find suitable pharmacophores for blocking each of these enzyme's activities -- that would be beneficial for human health. Our past successes with these methodologies have resulted in over 28 patents, 11 technologies and two startup companies.


No external funding.


Email Address of Submitting Author


Mayo Clinic


United States

ORCID For Submitting Author


Declaration of Conflict of Interest

Author's declare there are no conflicts of interest.